Business
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK
About this update from Nkarta, Inc.
[{"type":"text","content":"Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK Cells Derived from Peripheral Blood of Healthy Donors Induces Billion-Fold Expansion, Enabling Commercial-Scale Production of NK Cell Therapy from a Selected Single Donor SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of two preclinical data abstracts focused on its natural killer cell pipeline and proprietary manufacturing technology at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting and Pre-Conference Programs. \"Our presentations at this year's SITC meeting illustrate the inherent power and potential of donor-derived NK cells,” said James Trager, PhD, Chief Scientific Officer of Nkarta. “Nkarta’s research team has shown that our manufacturing platform technology can expand NK cells by well over a billion-fold, while maintaining their integrity and potency. These findings could prospectively allow us to derive our CAR NK products from a very limited set of stringently selected donors. In a second study, the team has also further built on the considerable potency of our CD19-directed CAR NK candidate, NKX019.” SITC 2022 abstracts will be available on the SITC website, https://www.sitcancer.org/2022/abstracts/abstract-titles-publications. Nkarta’s posters will be available for download at https://www.nkartatx.com/publications/ after 9:00 a.m. ET on November 10, 2022. Title: Large-scale expansion and engineering of human NK cells sourced from peripheral blood versus umbilical cord bloodAbstract Number: 381Poster Presentation Date and Time: November 10, 2022, 9:00 a.m. – 9:00 p.m. ETThis study illustrates a remarkable >250-billion fold expansion of NK cells derived from peripheral blood using Nkarta’s proprietary NKSTIM cell line. NK cells maintained their potency, and showed no signs of chromosomal aberrations over an extended period of expansion. Both the expansion capacity and potency of NK cells derived from adult donors compared favorably to those from cord blood. Phenotypic analysis of expanded cells demonstrated the selective expansion or differentiation of in vivo educated...